Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137710 | 1.00 | CYP2C19 (0.36) | CYP2C19CYP3A4F10ATMALDH1A1 | |
| SCHEMBL7624802 | 0.99 | CYP2C19 (0.35) | CYP2C19CYP3A4F10ATMALDH1A1 | |
| SCHEMBL5180173 | 0.96 | CYP2C19 (0.39) | CYP2C19CYP3A4F10ATMALDH1A1 | |
| SCHEMBL31695088 | 0.96 | CYP2C19 (0.39) | CYP2C19CYP3A4F10ATMALDH1A1 | |
| SCHEMBL28397691 | 0.86 | CYP2C19 (0.34) | CYP2C19CYP3A4F10ATMALDH1A1 | |
| SCHEMBL8545813 | 0.84 | CYP2C19 (0.39) | CYP2C19CYP3A4F10ATMALDH1A1 | |
| SCHEMBL14880000 | 0.83 | CYP2C19 (0.39) | CYP2C19CYP3A4F10ATMALDH1A1 | |
| SCHEMBL8980371 | 0.82 | CYP3A4 (0.33) | CYP3A4ALDH1A1TSHR | |
| SCHEMBL16491603 | 0.82 | CYP2C19 (0.34) | CYP2C19CYP3A4ATMALDH1A1CYP2C9 | |
| SCHEMBL31622117 | 0.82 | F10 (0.41) | F10ATMMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924327-A | Kras inhibitor compounds having macrocyclic structure | 上海湃隆生物科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| WO-2023099624-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | CYP2C19 1386/4885CYP3A4 1995/4885F10 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.